SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-21-021239
Filing Date
2021-11-03
Accepted
2021-11-02 18:02:02
Documents
14
Period of Report
2021-11-03
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K auph-20211103.htm   iXBRL 8-K 37973
2 EX-99.1 exhibit991_q32021pressrele.htm EX-99.1 120641
6 aurinalogoa.jpg GRAPHIC 11010
  Complete submission text file 0001628280-21-021239.txt   320785

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20211103.xsd EX-101.SCH 1942
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20211103_lab.xml EX-101.LAB 23970
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20211103_pre.xml EX-101.PRE 12668
7 EXTRACTED XBRL INSTANCE DOCUMENT auph-20211103_htm.xml XML 10774
Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8
Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36421 | Film No.: 211372815
SIC: 2834 Pharmaceutical Preparations